Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Whitehawk Therapeutics presented real-world analysis at ASCO 2026 confirming SEZ6 as a highly expressed target in small cell lung cancer (SCLC) and other neuroendocrine tumors. The data showed SEZ6 expression is at least 3-fold higher than established ADC targets like HER2, B7-H3, and DLL3 in SCLC, and 2- to 6-fold higher in prostate neuroendocrine carcinoma.
Key figures
- Drug Name
- HWK-206
- Sclc subtype coverage
- ~90%
- Sez6 expression vs pd1
- 3-fold higher
- Sez6 expression vs b7h3
- 3-fold higher
- Sez6 expression vs dll3
- 3-fold higher
- Sez6 expression vs her2
- 3-fold higher
- Sez6 expression vs pdl1
- 3-fold higher
- Sez6 expression prostate vs b7h3
- 2- to 6-fold higher
- Sez6 expression prostate vs dll3
- 2- to 6-fold higher
- Sez6 expression prostate vs trop2
- 2- to 6-fold higher
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.